Among adolescents aged 13 to 17 years, coverage with 1 or more Tdap dose increased from 89% to 91.3% from 2023 to 2024, respectfully.
Adolescent vaccination coverage improves for Tdap and MenACWY; HPV rates remain unchanged | Image Credit: © SewcreamStudio - © SewcreamStudio - stock.adobe.com.
Vaccination coverage with 1 or more doses of Tdap, MenACWY, meningococcal B vaccine; 3 or more doses of hepatitis B vaccine; and 2 or more doses of measles, mumps, and rubella (MMR) increased in 2024 among adolescents aged 13 to 17 years vs the prior year.1
According to August 14, 2025, data from the CDC's Morbidity and Mortality Weekly Report (MMWR), these increases highlight the progress in increased vaccination efforts in the adolescent population.
According to the MMWR, the Advisory Committee on Immunization Practices (ACIP) recommends 3 routine vaccines to adolescents aged 11 to 12 years:
A booster of MenACWY should be administered at age 16 years. The report stated the COVID-19 vaccine can be received and that those aged 16 to 23 years can receive serogroup B meningococcal vaccine (MenB). Additionally, adolescents should receive an annual influenza vaccination and catch up on any missed childhood vaccines. Since 2023, ACIP has recommended that pentavalent meningococcal vaccine (MenABCWY) can be used when both MenACWY and MenB are indicated at the same visit.1,2
The MMWR summarized coverage with these vaccines for 2024, not including influenza, COVID-19, and MenABCWY because of limited data. The report gathered data from the National Immunization Survey-Teen (NIS-Teen), an annual 2-phase survey that monitors vaccination coverage in the United States for adolescents aged 13 to 17 years. Phase 1 consists of a random-digit–dialed mobile telephone survey of parents or guardians (parents) in households with eligible adolescents aged 13 to 17 years. Phase 2 is a mailed survey to the adolescent's vaccination providers previously identified by the parent or guardian to obtain vaccine history.1
The household response rate was 21.0%. Adequate provider data was received from providers for 42.8% of adolescents with completed interviews. These 2 rates reflect different types of response mechanisms. The household response rate measures participation by households that completed the household interviews, whereas the adequate provider data rate measures vaccination data availability among those who completed the household interviews.
"To address low response rates, nonresponse adjustments are incorporated in the weighting to reduce potential bias," wrote the MMWR authors. "In addition, statistical modeling techniques such as imputation and variance estimation methods are used to handle missing data and account for the complex survey design."
Among adolescents aged 13 to 17 years in 2024 coverage increases were as follows, compared to 2023:
Other recommended vaccine coverage increased, as did catch-up vaccination in 2024 compared to 2023, including for:
In 2024, 78.2% of adolescents aged 13–17 years had received ≥1 dose of HPV vaccine, and 62.9% were up to date with the HPV vaccination series, similar to 2023 estimates (76.8% and 61.4%, respectively), the authors noted.
Overall, 1 or more dose of Tdap coverage and 1 or more dose of MenACWY coverage was 90% or greater in a majority of states, highlighting progress in public health initiative and activities to improve coverage.
"A strong provider recommendation is associated with increased likelihood of being vaccinated however, in this analysis, adolescents living in mostly rural areas were less likely to receive an HPV vaccination recommendation from a provider than were those living in mostly urban areas," wrote the MMWR authors. In 2024, ≥1-dose HPV coverage and the percentage of adolescents up to date with HPV vaccination were consistently higher among those who received a provider recommendation for vaccination."
Reference:
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.
